TCA17 Antibody

What is TCA17 and what are its known functions in cellular processes?

TCA17 (Transport protein particle Complex-Associated protein 17) is a sedlin-like protein that functions as a TRAPPII-specific subunit, first identified in yeast as encoded by the non-essential ORF YEL048c. The protein adopts a fold conformation resembling the N-terminal longin domain of certain SNAREs, suggesting its role in facilitating the recognition of distinct SNAREs during vesicle fusion .

TCA17 has several cellular functions:

• Participates in the Golgi-endosomal recycling of Snc1 (a v-SNARE) in yeast

• Stabilizes the interaction between TRAPPII-specific subunits and the core complex

• Regulates proper localization of Rab GTPases (particularly Ypt31/Ypt32)

• In Candida albicans, TCA17 is involved in secretion-related vesicle transport and plays roles in cell wall integrity, vacuolar function, and virulence

How should I design experimental controls when working with TCA17 antibodies?

When working with TCA17 antibodies, robust experimental controls are crucial:

• Negative controls:

  • Non-specific IgG of the same isotype and species as your TCA17 antibody

  • Samples from TCA17 knockout/knockdown cells or organisms (when available)

  • Pre-immune serum controls for custom-developed antibodies

• Positive controls:

  • Recombinant TCA17 protein or TCA17-overexpressing cells

  • Tissues/cells known to express TCA17 at detectable levels

  • For co-IP experiments, include known interacting partners of TCA17 (e.g., Trs130 in yeast)

• Specificity controls:

  • Peptide competition assays to confirm epitope specificity

  • Cross-validation with multiple antibodies targeting different epitopes of TCA17

  • Parallel detection with orthogonal methods (e.g., mass spectrometry)

For immunofluorescence studies, include control samples treated with brefeldin A (5 μg/ml) or nocodazole (10 μg/ml) which may alter the subcellular distribution of TRAPP complex components .

What methods are most reliable for validating a new TCA17 antibody?

A comprehensive validation protocol for new TCA17 antibodies should include:

• Western blot validation:

  • Confirm single band at the expected molecular weight (~17 kDa for yeast Tca17)

  • Compare with positive and negative cell/tissue controls

  • Perform detection in wild-type vs. TCA17 knockout/knockdown samples

• Immunoprecipitation validation:

  • Verify ability to pull down endogenous TCA17

  • Confirm co-precipitation of known TRAPP complex components

  • Analyze by mass spectrometry to confirm identity

• Immunofluorescence/Immunohistochemistry validation:

  • Demonstrate expected subcellular localization pattern

  • Show reduced/absent signal in knockout/knockdown cells

  • Compare with other validated markers of the TRAPP complex

• Cross-reactivity testing:

  • Test against similar sedlin-like proteins (e.g., Trs20)

  • Evaluate performance across species if cross-reactivity is claimed

  • Peptide array analysis to confirm epitope specificity

How can I distinguish between TCA17's role in the TRAPP complex versus potential independent functions?

This challenging question requires multiple complementary approaches:

• Targeted mutagenesis strategy:

  • Generate point mutations that specifically disrupt TCA17's interaction with TRAPP complex components while preserving protein stability

  • Create chimeric proteins swapping domains between TCA17 and related proteins like Trs20

  • Use these constructs in rescue experiments with TCA17-deficient cells

• Biochemical fractionation:

  • Perform size-exclusion chromatography to separate TRAPP-associated and free TCA17

  • Analyze each fraction for TCA17-dependent phenotypes

  • Conduct immunoprecipitation with antibodies against different TRAPP components to identify TCA17 populations not associated with the complete complex

• Proximity labeling approaches:

  • Fuse TCA17 with BioID or APEX2 to identify proximity interactions in living cells

  • Compare interactome data with known TRAPP components

  • Identify potential TRAPP-independent interaction partners

• Temporal analysis:

  • Use rapid induction/degradation systems to distinguish immediate versus delayed consequences of TCA17 manipulation

  • Acute loss of TRAPP complex function versus specific loss of TCA17 may reveal independent roles

What are the key considerations when developing antibodies to distinguish between TCA17 and its closely related paralog TRAPPC2L?

Developing antibodies that can definitively distinguish between TCA17 and TRAPPC2L (both sedlin-like proteins) requires:

• Epitope selection strategy:

  • Perform sequence alignment to identify regions with minimal homology

  • Focus on unique loops or terminal regions rather than conserved structural elements

  • Consider 3D structural analysis to identify surface-exposed epitopes unique to each protein

• Validation requirements:

  • Test against recombinant TCA17 and TRAPPC2L in parallel

  • Validate in cells with individual knockouts of each protein

  • Perform epitope mapping to confirm exact binding regions

• Application-specific considerations:

  • For Western blots, select antibodies targeting regions that remain accessible in denatured state

  • For immunoprecipitation, target conformational epitopes that don't interfere with protein-protein interactions

  • For immunofluorescence, validate that epitopes are accessible in fixed cells

• Advanced specificity testing:

  • Employ competitive binding assays with increasing concentrations of recombinant proteins

  • Use quantitative cross-reactivity analysis to determine specificity ratios

  • Consider humanized yeast models expressing either protein for specificity testing

How can I use TCA17 antibodies to investigate TRAPP complex assembly dynamics in disease models?

To investigate TRAPP complex assembly dynamics in disease models:

• Immunoprecipitation-based complex analysis:

  • Use TCA17 antibodies for co-immunoprecipitation followed by quantitative proteomics

  • Compare stoichiometry of co-precipitated TRAPP components in healthy versus disease states

  • Assess changes in complex composition following cellular stress or drug treatments

• Live-cell imaging approaches:

  • Combine TCA17 antibody fragments (e.g., scFv) with cell-penetrating peptides

  • Use complementary fluorescent protein systems to monitor association/dissociation events

  • Employ FRET or BiFC assays to detect specific TCA17 interactions in living cells

• Pulse-chase analysis of complex assembly:

  • Use metabolic labeling combined with sequential immunoprecipitation

  • Track newly synthesized TCA17 incorporation into existing TRAPP complexes

  • Compare assembly kinetics between normal and disease models

• Fractionation techniques:

  • Employ glycerol gradient centrifugation to separate different TRAPP complexes

  • Use antibodies against TCA17 and other TRAPP components to identify subcomplexes

  • Compare fractionation profiles between health and disease states

What methodological approaches can resolve contradictory findings about TCA17's role in autophagy versus secretory pathways?

To address contradictory findings regarding TCA17's function:

• Conditional knockout/knockdown systems:

  • Use tissue-specific or inducible TCA17 deletion models

  • Compare acute versus chronic loss of TCA17 function

  • Analyze effects in different cell types that may have distinct pathway dependencies

• Functional separation approaches:

  • Design domain-specific TCA17 mutants that selectively disrupt secretory or autophagic functions

  • Perform structure-function analysis with chimeric proteins

  • Use compartment-targeted TCA17 to distinguish pathway-specific roles

• Temporal analysis protocols:

  • Conduct time-course experiments following TCA17 depletion/restoration

  • Determine whether secretory defects precede autophagy defects or vice versa

  • Use synchronized cells to assess cell cycle-dependent functions

• Multi-parameter analytical methods:

  • Combine high-content imaging with biochemical assays

  • Measure multiple pathway outputs simultaneously

  • Apply systems biology approaches to model pathway interdependencies

What expression systems are most effective for generating recombinant TCA17 for antibody production?

The choice of expression system for recombinant TCA17 production is critical for obtaining properly folded protein for immunization:

For optimal results:

• Express full-length TCA17 and domain-specific constructs in parallel

• Include fusion tags that aid in purification without interfering with structure

• Validate protein folding using circular dichroism or limited proteolysis before immunization

• Consider co-expression with stabilizing TRAPP complex partners for conformational epitopes

How can I optimize immunoprecipitation protocols for studying TCA17 interactions with the TRAPP complex?

Optimizing immunoprecipitation of TCA17 with TRAPP complex components requires:

• Buffer optimization:

  • Use buffers containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 0.1% NP-40 for basic interactions

  • For detecting weaker interactions, reduce NaCl to 100 mM and add 10% glycerol

  • For studying interactions with membrane-associated components, include 10 mM EDTA

• Antibody considerations:

  • Use antibodies targeting different epitopes of TCA17 to avoid blocking interaction surfaces

  • Compare polyclonal and monoclonal antibodies for optimal complex recovery

  • Consider direct antibody conjugation to beads to avoid interference from heavy chains

• Cross-linking approaches:

  • For transient interactions, use reversible cross-linkers like DSP (dithiobis[succinimidyl propionate])

  • Titrate cross-linker concentration to preserve specificity

  • Include matched non-specific IgG controls processed identically

• Detection methods:

  • For known interactions, use targeted Western blotting

  • For comprehensive complex analysis, employ mass spectrometry

  • Consider multiplex approaches to simultaneously monitor multiple components

What are the specific challenges in developing antibodies against human TRAPPC2L compared to yeast TCA17?

The development of antibodies against human TRAPPC2L presents unique challenges compared to yeast TCA17:

• Sequence conservation considerations:

  • Human TRAPPC2L shares only 33% identity and 54% similarity with yeast TCA17

  • Conserved functional domains may be less immunogenic

  • Target species-specific regions while ensuring functional relevance

• Structural challenges:

  • The longin domain structure (120-140 amino acids) common to both proteins is highly conserved

  • Human TRAPPC2L may have different post-translational modifications

  • Conformational epitopes may differ despite sequence homology

• Validation complexity:

  • Need to test cross-reactivity against multiple human paralogs (TRAPPC1, TRAPPC2, etc.)

  • Require human cell lines with CRISPR knockout for proper validation

  • Consider humanized yeast models expressing human TRAPPC2L for specificity testing

• Application-specific optimizations:

  • For immunohistochemistry, consider tissue-specific fixation protocols

  • For immunoprecipitation, optimize detergent conditions for human cell membranes

  • For immunofluorescence, account for differences in subcellular localization patterns

What quantitative methods can assess TCA17 antibody specificity across different experimental conditions?

Quantitative assessment of TCA17 antibody specificity includes:

• Competitive binding analysis:

  • Perform dose-response ELISA with recombinant TCA17 and related proteins

  • Calculate EC50 values and specificity indices

  • Determine cross-reactivity ratios under varying buffer conditions

• Surface plasmon resonance (SPR) characterization:

  • Measure binding kinetics (kon, koff) and affinity (KD)

  • Compare binding parameters between target and potential cross-reactive proteins

  • Evaluate antibody performance under different pH, salt, and detergent conditions

• High-throughput proteome screening:

  • Test antibody against protein microarrays containing related TRAPP components

  • Quantify signal-to-noise ratios across thousands of proteins

  • Identify potential unexpected cross-reactivities

• Cellular validation metrics:

  • Quantify signal reduction in TCA17 knockdown/knockout models

  • Perform immunoprecipitation followed by mass spectrometry to calculate enrichment factors

  • Assess consistency of results across different cell types and experimental conditions

How can humanized yeast models be leveraged for studying TCA17 antibody specificity and function?

Humanized yeast models offer powerful platforms for TCA17 research:

• CRISPR-based humanization strategy:

  • Replace yeast BET5 (ortholog to human TRAPPC1) with human TRAPPC1 gene using scarless editing

  • Create parallel models with wild-type and mutant human TRAPPC1 variants

  • Use these systems to test antibody specificity across species barriers

• Application to antibody validation:

  • Compare antibody binding to humanized versus native yeast TCA17

  • Test cross-reactivity against humanized variants of related proteins

  • Use flow cytometry or microscopy-based assays to quantify binding in intact cells

• Mutation analysis framework:

  • Introduce patient-derived mutations into humanized systems

  • Use antibodies to track changes in protein localization or complex formation

  • Correlate antibody-based observations with functional phenotypes

• Advantages over mammalian systems:

  • Precise genetic control with lower genetic redundancy

  • Rapid generation of multiple variants in parallel

  • Ability to study lethal mutations in conditional systems

What are the latest developments in computational approaches for TCA17 antibody design and epitope prediction?

Recent computational approaches for TCA17 antibody design include:

• Structure-based antibody design:

  • Use atomic-accuracy structure prediction to design antibodies with custom specificity profiles

  • Generate antibodies that can distinguish between closely related subtypes or mutant proteins

  • Design antibodies even when experimentally resolved target structures are unavailable

• Machine learning approaches:

  • Train models on experimentally selected antibodies to identify distinct binding modes

  • Use these models to predict and generate specific variants beyond those observed in experiments

  • Optimize antibodies for both specific binding to single targets and cross-specificity for multiple targets

• Epitope mapping innovations:

  • Apply biophysics-informed modeling to identify immunogenic regions

  • Predict conformational epitopes based on protein dynamics simulations

  • Design epitope-specific antibodies with improved specificity for distinguishing between TCA17 and related proteins

• Library design strategies:

  • Create targeted libraries focused on optimizing CDR regions for TCA17 binding

  • Combine computational design with high-throughput screening

  • Develop antibodies with tailored properties for specific research applications

How can I develop TCA17 antibodies suitable for tracking dynamic changes in TRAPP complex composition in living cells?

Developing antibodies for tracking TRAPP complex dynamics in living cells:

• Antibody fragment engineering:

  • Convert conventional antibodies to smaller formats (Fab, scFv, nanobodies)

  • Optimize for intracellular expression and stability

  • Ensure minimal interference with TCA17 function and complex formation

• Live-cell compatible labeling:

  • Fuse antibody fragments with fluorescent proteins or self-labeling tags

  • Consider split fluorescent protein approaches for detecting specific interactions

  • Use photoactivatable or photoswitchable fluorophores for pulse-chase experiments

• Delivery strategies:

  • Optimize cell-penetrating peptide conjugation for direct delivery

  • Develop reversible permeabilization protocols that preserve cell viability

  • Consider intracellular expression using transient transfection or stable cell lines

• Validation in dynamic systems:

  • Test antibody performance during cell cycle progression

  • Verify functionality under various stress conditions

  • Compare with orthogonal approaches (e.g., fluorescent protein fusions)

What quality control parameters should be established for TCA17 antibodies used in high-resolution imaging techniques?

For TCA17 antibodies in high-resolution imaging:

• Spatial resolution metrics:

  • Determine point spread function using sub-diffraction beads

  • Measure effective resolution by analyzing minimal distinguishable distances

  • Quantify signal-to-noise ratio under typical imaging conditions

• Specificity parameters:

  • Calculate the percentage of signal reduction in TCA17 knockdown controls

  • Measure co-localization coefficients with orthogonal TRAPP markers

  • Determine background levels in subcellular compartments where TCA17 is absent

• Quantitative performance standards:

  • Establish lot-to-lot consistency thresholds for key parameters

  • Define acceptable ranges for antibody titration curves

  • Create reference images for quality control comparison

• Application-specific validations:

  • For super-resolution microscopy: verify epitope accessibility after sample preparation

  • For electron microscopy: confirm antibody performance with different fixation protocols

  • For correlative microscopy: ensure compatibility with multi-technique sample processing